Key Takeaways from Analyst
The hypercalcemia treatment industry is expected to grow at a steady pace over the forecast period driven by the rising prevalence of hypercalcemia worldwide.
North America currently dominates the market owing to advanced healthcare infrastructure and growing awareness levels. However, Asia Pacific is expected to emerge as the fastest growing regional market in the coming years with China and India likely to spearhead demand.
Furthermore, side effects associated with long-term usage of bisphosphonates could shift demand towards alternative treatments. Calcitonin offers an adjunct therapeutic option but its short term effectiveness and availability of cost-effective generics are key challenges. Emerging therapies targeting PTH and fibroblast growth factor 23 could gain market share if demonstrate better clinical outcomes and safety profiles.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients